Olema will use the financing proceeds to advance the clinical development of OP-1250, its lead product candidate in breast cancer, and expand ongoing research and development activities.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

665 3rd St. 250
San Francisco, CA 94107
USA

Phone

Undisclosed

Website

www.olema.com

Email Address

[email protected]

Overview

Olema Oncology (Nasdaq: OLMA) is a biopharmaceutical company developing innovative targeted therapies for women's cancers. The Company's lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Sean Bohen

Chief Medical Officer

Pamela Klein

Chief Operating Officer

Shane Kovacs

Chief Scientific Officer

Peter Kushner

Chief Technical Officer

Cyrus Harmon

VP - Bus. Development

Kinney Horn

VP - Bus. Development

David Myles

VP - General Counsel

John Moriarty

Browse more venture capital transactions:

Prev: 10/2/2020: ScriptDrop venture capital transaction
Next: 10/3/2020: Braintrust venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary